Clinical and immunological differences between asymptomatic HDM‐sensitized and HDM‐allergic rhinitis patients

Summary Background Confirmation of the clinical relevance of sensitisation is important for the diagnosis of allergic rhinitis. Objective To investigate the usefulness of an in vitro basophil activation test and component‐resolved diagnosis in distinguishing between symptomatic allergic rhinitis pat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical and experimental allergy 2019-06, Vol.49 (6), p.808-818
Hauptverfasser: Zidarn, Mihaela, Robič, Maša, Krivec, Anja, Šilar, Mira, Resch‐Marat, Yvonne, Vrtala, Susanne, Kopač, Peter, Bajrović, Nissera, Valenta, Rudolf, Korošec, Peter
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Summary Background Confirmation of the clinical relevance of sensitisation is important for the diagnosis of allergic rhinitis. Objective To investigate the usefulness of an in vitro basophil activation test and component‐resolved diagnosis in distinguishing between symptomatic allergic rhinitis patients and asymptomatic sensitization to house dust mites (HDMs). Methods Thirty‐six subjects with a positive skin prick test (SPT) for HDM were divided into a symptomatic (n = 17) and an asymptomatic (n = 19) group on the basis of their clinical history and a nasal provocation test. A basophil CD63 response to in vitro stimulation with Dermatophagoides pteronyssinus whole allergen extract and the IgE reactivity profiles for Der p 1, 2, 4, 5, 7, 10, 11, 14, 15, 18, 21, 23 were evaluated. Serum IgE and IgG specific to D pteronyssinus whole allergen extract and total IgE were measured. Results There were no statistically significant differences in the levels of IgE (IgE levels were higher in symptomatic patients with P = 0.055) and IgG specific to D pteronyssinus and total IgE. Symptomatic patients showed a lower threshold for in vitro basophil activation (3.33 ng/mL vs 33.3 ng/mL), a higher area under the curve (AUC) of basophil activation (171 vs 127) (P = 0.017), a higher response to positive control with anti‐FcεRI stimulation (97% vs 79%) (P 
ISSN:0954-7894
1365-2222
DOI:10.1111/cea.13361